Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He's starting to lose faith:
"$7.00 or Nothing"
"Imagine the number of zeros on your accounts at $3 buyout."
❌️ Money for share buyback
No money for share buyback. Need money for the following:
✅️ Mikah profit splits ($1,858,629 remaining)
✅️ Hakim Promissory Note ($4,000,000 plus interest)
✅️ Caskey Promissory Note ($1,000,000 plus interest)
✅️ Mikah Adderall ownership (Purchase price currently in discussions)
At what point will the BOD and CEO agree to support their company by systematically buying back a few million shares a day ???????
✅️ PANIC MODE ACTIVATED
Purdue is FREAKING OUT because they know they have no case.
This is why they added the additional patent AFTER the original complaint.
and in fact adds an additional patent filed by Purdue after the original complaint was submitted.
Quick note that Q4 is up at end of March, which means the 10K is due 90 days after year end. Last year they filed on 7/1. This year they will file on 6/30 due to 90 day mark falling over the weekend.
Many catalysts on deck fueling ELTP to rocket up again.
1. Launch of generic Percocet in less than 12 days.~$500 million market
2. Launch of generic Dolophine (methadone) ~before or on 5/30/25 ~$30 million market
3. Pending acquisition and merger news.
4. Pending generic Adderall IR launch in Israel.
5. Pending positive ruling for Elite with generic OxyContin.
6. Record breaking quarterly revenue report on 06/15/25.
7. April 1 - Elite terminates Prasco Agreement and begins marketing Adderall XR 100% by themselves.
8. April 2 - Tariffs begin
9. Dopamine Agonist approval
10. Indian R&D Agreement signed
11. Positive BE studies (Concerta and Undisclosed)
ELTP
Eltp 2025
Other company 2026
Other company 2027
2025 Fiscal Q4: $120 million run rate
2026 Fiscal Q1: $160 million run rate
2026 Fiscal Q2: $200 million run rate
$200 million run rate.
$200 million run rate.
Imagine
The number of zeros on your accounts at $3 buyout.
My favorite Kool Aid is tropical punch. My favorite stock is ELTP.
NASDAQ2020
Re: HenryB3 post# 422182
Tuesday, March 04, 2025 4:15:57 PM
Post# of 423258
$40 to $60 million current dollar quarter will get us near DollarLand
First quarter of Vyvanse sales and shippment.
First shipment to Israel for Adderall
Two more opioids to be launched.
ITS HAMMERTIME !!!!!!!!
Im Toppin off before THE Buyout.
It’s peanuts compared to last two months. Only kamikazes short a stock where the ceo announced he is hunting for buyout lol.
Recent ELTP FINRA Short Volume ramping up
2025-03-20 247,078
2025-03-19 131,049
2025-03-18 89,826
2025-03-17 75,024
2025-03-14 12,535
2025-03-13 30,421
2025-03-12 117,463
2025-03-11 159,511
2025-03-10 111,907
2025-03-07 241,998
I agree, despite my facetiousness. June/August will tell us everything we need to know finally..the who, the why and the where...thank khrist.
Ole Henry tried to warn the Kool aide drinkers. The red flags are there. Bridges are not going to be cheap, only the stupid will pay. Sub 12 is coming.
Percocet is launching on one of these days:
Monday, March 24
Tuesday, March 25
Monday, March 31
As per NH we are a week or two from the launch of Percocet.
Elite is no longer paying overtime pay because of the new facility approval.
Financials are going to look even better moving forward.
Obviously, Elite's next two reports (June and August) are going to be amazing, but Elite's Fiscal Q2 quarter being reported in mid-November is going to be WILD.
It will be Elite's FIRST quarter with EVERY SINGLE DRUG Elite has having a FULL quarter of sales, which will include all the drugs repurchased from Nostrum AND our Adderall launch in Israel.
I'm expecting $50+ million in revenue for the Fiscal Q2 quarter.
And as I previously stated, we will be on the NASDAQ by this time so we're gonna REALLY start to get noticed.
Thanks.
IMO .45 level continues to be a tough nut to crack even without the INTL OR ETRF bids. There was a MM on top of both bid / ask earlier selling to themselves to drop the price. Maybe done just so these large orders could fill.
I don't hold enough shares to feel a lot of pain..but those holding maybe (and that's a big maybe) a million or more shares are thinking "could have sold around 75 level when the volume was so high...God help me if Wetscent is right and this CEO IS a crook..and those billion OS will always be a huge drag on any upside from here...and maybe even take the SP lower...WHY didn't I listen???"
Can’t be. I got some of them. 😀
Can’t be. I got some of them. 😀
I’ll play a little devils advocate on this one. While the numbers you posted may be true, I would assume that the drugs are probably being manufactured overseas because it’s cheaper. To get the true value, you would need to know production costs differences as well
I bought all his shares @ 15
As I said, been watching level II and they got filled.
So ... If an overseas company sold 5 Billion dollars of pharmaceuticals per year to the United States, there are 25% tariffs, and it took 5-10 years to open a brand new manufacturing facility on US soil.
$5 billion x 5 years x 25% tariffs = $6.25 billion wasted being spent on tariffs
For double that at 10 years = $12.5 billion wasted being spent on tariffs
Makes one wonder from their viewpoint, considering it could save them many billions in the long term, how many billions they might be willing to spend just to aquire a pharmaceutical manufacturing plant on US soil alone.
About INTL FCStone Inc.
The company serves institutional investors, brokers, professional traders, CTA/CPOs, proprietary trading groups, commercial banks and major investment banks. Headquartered in New York City , the company is listed on NASDAQ under the ticker symbol "INTL".
That is unlikely as average daily volume under half a million the past 2 weeks. You can sometimes be fooled when anothecustomer who uses the same MM bids higher. EG if your broker uses INTL and you bid .4513 the 200k offer at .4512 will disappear until the .4513 is hit.
The same MM bidding 500K in two separate transaction that got filled in the past two weeks. The buyer (if the same) must have accumulated more than a million already. Been watching level II.
200k on bid now at .4512 by MM INTL for those interested in selling some size.
I wii restrain myself this time
ANother way is to tell ALL your friends and family to buy more - because this will be SPECTACULAR very soon.
I miss the catalysts
It is perfectly relevant..and a very good question...but you won't get an answer from the majority on this board
I doubt it too, but I’m still watching just in case.
No investors should be selling right now. Long or short. Let the MM do their thing and look for a quick chance at a bargain.
As per NH we are a week or two from the launch of Percocet. News can hit at any time.
Current volume is meaningless although it permits MMs to F around until real buyers step in. The general stock market malaise doesn't help. I doubt we will reach your downside conjecture but you never know.
Order lifting stay was signed yesterday. Purdue now has until April 19 to file the Amended Complaint. And the beat goes on.
New from yesterday, Purdue vs Elite
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
So this is coming around whilst Purdue is trying to settle.
As the say,
You start getting the most flak when your over the target
This is all just conjecture on my part.
To get strong buying here again I think we either need news or we need the price to drop low enough for one of the following to start buying:
a) large (financially flush shareholders) want to buy more,
b) retail that has been debating whether to invest will decide to take a position,
c) the 2 buck investor decides he should sell his car to one of those instant car purchase companies
News probably won't hit for another couple of weeks. Until then the price could be slowly drug down and never get so low for significant more buyers to be enticed. If this plays out I think the price will stay above 40cents.
Another possibility is that someone holding a relatively large number of shares throws in the towel and liquidates their position. That would be odd at this point because most people with lots of shares that couldn't handle the long wait for Q4 revs have already taken their profit. Existing shareholders with hundreds of thousands of shares are very unlikely to give up now when we know Q4 revs are to to triple. But it possible that someone has financial pressures and they simple have to get some cash. If that is going to happen I think it will be soon because the low 40 cent range could cause a some existing shareholders to freak out a bit.
If there is a big dump of shares I think it will be very brief, but it could hit the mid 30s before recovering. The recovery after any such dump would probably take us back to the 50cent range due to the increase in volume pulling in more eyes. I'm keeping a very close eye on price right now because if that happens I want to grab me some more shares in the mid 30cent range. I have more shares than I need now, but it would feel dumb not to get more at that price.
Houston , we have a problem. It’s called Nasrat and his unwillingness to sell elite asap. Why is the real question. My guess, it’s MIKAH related. Is that fair to us. Nope
Just my opinion
Wonder where this bottom is? Doesn’t look good…
I forgive you as long as you post no bills.
What we need is for you to go away like you said you would over and over again The pps hit your goodbye number Remember you were totally out at 15 So keep your word (if you have one ) and go Pleade!!
Sorry about the real long last post I was only supposed to copy one paragraph about Pfizer, wanting mergers acquisitions with generic pharmaceutical stateside
thank you very much for making a buy back irrelevant. Told ya ! im not thinking with a broad brush. Your points of using cash reserves for growth are spot on. Again thanks
To repurchase shares, the company is NOT required to Slap The Big Fat Ask !!!!!!!!!!!!
They can use limit orders,
IB_🤴
Plus a few million shares will make no noticeable difference in share price. We're talking millions would need to be retired and by then the price will no longer be close to where it is now. And Elite can use the monies for better things like raw materials and potentially additional staff and sales. True we now have the physical infrastructure to grow but people needs will be greater the more we sell.
There is no chance the company will do a share buyback. The company does not need to be supported which is unfortunately not the position of my ex wife.
Relax. The stock will take care of its own support based upon strong fundamentals and merger activity. It remains an excellent buying opportunity at current prices.
Followers
|
1105
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
423270
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators Dr Speculator Ninja mrwrn2010 NASDAQ2020 namtae |
Senior Moderator: IB_
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 85,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite, Dexcel |
Adderall XR | 1.56 B | On Market | 10 | Elite, Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 47 M | On Market | 5 | Elite |
Dopamine Agonist | 12 M | Filed with FDA - Dec 22, 2022 | ---------- | ---------- |
Methotrexate | 63.4M | On Market | 8 | Elite |
Percocet | 500 M | Approved in Launch Queue | 14 | ---------- |
Norco | 300 M | On Market | 12 | Elite |
Methadone | 30 M | Approved in Launch Queue | 8 | ---------- |
OxyContin | 720 M | Filed with FDA - Aug 17, 2023 | 4 | ---------- |
Vyvanse | $4.30 B | On Market | 13 | Elite |
Concerta | 1.16 B | BE Studies | 8 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
2025 Q-1 | 18,803,000 | +109.39% | 3,864,056 | +144.00% |
2025 Q-2 | 18,880,000 | +33.00% | 3,500,000 | +84.00% |
2025 Q-3 | 14,400,000* | -8.00% | 1,100,000 | -69.00% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |